The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The use of real-world data in drug repurposing
Open accessAbstract
Drug repurposing, or repositioning, is to identify new uses for existing drugs. Significantly reducing the costs and time-to-market of a medication, drug repurposing has been an alternative tool to accelerate drug development process. On the other hand, 'real world data (RWD)' has been also increasingly used to support drug development process owing to its better representing actual pattern of drug treatment and outcome in real world. In the healthcare domain, RWD refers to data collected from sources other than traditional clinical trials; for example, in electronic health records or claims and billing data. With the enactment of the 21st Century Cures Act, which encourages the use of RWD in drug development and repurposing as well, such increasing trend in RWD use will be expedited. In this context, this review provides an overview of recent progresses in the area of drug repurposing where RWD was used by firstly introducing the increasing trend and regulatory change in the use of RWD in drug development, secondly reviewing published works using RWD in drug repurposing, classifying them in the repurposing strategy, and lastly addressing limitations and advantages of RWDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The use of real-world data to investigate drug repurposing signals has become an appealing approach (Xu et al., 2015;Park, 2021;Liu and Panagiotakos, 2022;Zong et al., 2022)”
From Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review (2023) · cites this paper as Park, 2021
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
George, H., Duke Jon, D., Shah Nigam, H., Reich Christian, G., Vojtech, H., Schuemie Martijn, J., Suchard Marc, A., Woong, P. R., Kei, W. I. C., Rijnbeek Peter, R., et al. (2015) · Studies in Health Technology and Informatics · doi:10.3233/978-1-61499-564-7-574 · Cited by 1,107 · cited 1×
“One such example is found in Observational Health Data Sciences and Informatics (OHDSI) consortium [33].”
BackgroundMetformin Associated With Lower Cancer Mortality in Type 2 Diabetes
Landman, G. W. D., Kleefstra, N., van Hateren, K. J. J., Groenier, K. H., Gans, R. O. B., & Bilo, H. J. G. (2010) · Diabetes Care · doi:10.2337/dc09-1380 · Cited by 502
Research works printed but not linked: 28
- Langedijk, 2015, Drug Discov Today, 20, 1027, 10.1016/j.drudis.2015.05.001 · DOI
- Ashburn, 2004, Nat Rev Drug Discov, 3, 673, 10.1038/nrd1468 · DOI · Paper page
- Cha, 2018, Br J Pharmacol, 175, 168, 10.1111/bph.13798 · DOI
- Park, 2019, Transl Clin Pharmacol, 27, 59, 10.12793/tcp.2019.27.2.59 · DOI
- FDA. Promoting effective drug development programs: opportunities and priorities for FDA's office of new drugs - November 7, 2019 (March 31, 2020). Accessed September 27, 2021. https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/promoting-effective-drug-development-programs-opportunities-and-priorities-fdas-office-new-drugs
- Sherman, 2016, N Engl J Med, 375, 2293, 10.1056/NEJMsb1609216 · DOI
- Currie, 2012, Diabetes Care, 35, 299, 10.2337/dc11-1313 · DOI
- Evans, 2005, BMJ, 330, 1304, 10.1136/bmj.38415.708634.F7 · DOI · Paper page
- Xu, 2015, J Am Med Inform Assoc, 22, 179, 10.1136/amiajnl-2014-002649 · DOI
- Visanji, 2021, Pharmacoepidemiol Drug Saf, 30, 201, 10.1002/pds.5176 · DOI
- Kuang, 2019, Methods Mol Biol, 1903, 255, 10.1007/978-1-4939-8955-3_15 · DOI
- Suchard, 2013, Drug Saf, 36, S83, 10.1007/s40264-013-0100-4 · DOI
- Wu, 2019, JCO Clin Cancer Inform, 3, 1, 10.1200/CCI.19.00001 · DOI
- Ozery-Flato, 2020, JAMIA Open, 3, 536, 10.1093/jamiaopen/ooaa048 · DOI
- Laifenfeld, 2021, Front Pharmacol, 12, 631584, 10.3389/fphar.2021.631584 · DOI
- Brilliant, 2016, Am J Med, 129, 292, 10.1016/j.amjmed.2015.10.015 · DOI
- Lopez, 2008, PLoS Biol, 6, e236, 10.1371/journal.pbio.0060236 · DOI
- Falk, 2012, J Biomed Biotechnol, 2012, 278932, 10.1155/2012/278932 · DOI
- Goldstein, 2018, Pharmacol Res, 130, 44, 10.1016/j.phrs.2018.02.013 · DOI
- Zhou, 2021, Mol Psychiatry
- Zhou, 2020, Bioinformatics, 36, i436, 10.1093/bioinformatics/btaa451 · DOI
- Nagashima, 2016, Sci Rep, 6, 26375, 10.1038/srep26375 · DOI
- Paik, 2015, Sci Rep, 5, 8580, 10.1038/srep08580 · DOI
- Boland, 2013, J Am Med Inform Assoc, 20, e232, 10.1136/amiajnl-2013-001932 · DOI
- Holford, 2010, Clin Pharmacol Ther, 88, 166, 10.1038/clpt.2010.114 · DOI
- Hernán, 2016, Am J Epidemiol, 183, 758, 10.1093/aje/kwv254 · DOI · Paper page
- Chen, 2021, Drug Discov Today, 26, 1256, 10.1016/j.drudis.2020.12.013 · DOI
- Hripcsak, 2015, Stud Health Technol Inform, 216, 574
Cited by
Sorted by citations
Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
Grabowska, M. E., Huang, A., Wen, Z., Li, B., & Wei, W.-Q. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1257700 · Cited by 55
“In vivo validation included animal models, randomized controlled trials, and real-world data (de fi ned as patient data collected outside of clinical trials — e.g., data from electronic health records [EHRs] and health insurance claims data (Park, 2021)).”
Method
Metadata
- Authors
- Park, K.
- Affiliations
- Yonsei University (KR)
- Corresponding author
- Park, Kyungsoo
- ORCID
- Park, Kyungsoo
- Venue
- Translational and Clinical Pharmacology
- Publisher
- XMLink
- Published
- 2021
- Volume
- 29
- Issue
- 3
- Pages
- 117
- ISSN
- 2289-0882 (ISSN-L)
- 2383-5427
- PMC
- PMC8492393
- OpenAlex
- W3203973511
- Cited by
- 22
- References
- 2
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 7 · 2023: 2 · 2022: 3
- FWCI
- 0.59
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- Locations
- Translational and Clinical Pharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Keywords
- drug repurposing, real-world data, drug development, electronic health records, 21st Century Cures Act, regulatory policy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
